Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
NCT03130764Phase 2Withdrawn
- Sponsor
- Columbia University
- Start
- Mar 2017
- Primary completion
- Nov 2017
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in non-small cell lung cancer (NSCLC), sponsored by Columbia University. Planned start Mar 2017; status: withdrawn.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03130764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03130764.